Their findings demonstrated that an amniotic membrane-derived matrix could potentially influence the healing response following cardiac injury.
That study was independent of Ferrer's current biotechnology project, but it illustrates why scientists consider amniotic membrane-inspired materials worth exploring.
The broader field has accumulated encouraging experimental evidence.
The remaining challenge is determining whether a particular formulation can provide a reliable, clinically meaningful benefit in human patients.
Why Regenerating Heart Tissue Is So Difficult
If the concept of supporting healing through a hydrogel seems straightforward, the underlying biology is anything but simple.
The adult human heart contains specialized muscle cells called cardiomyocytes.
These cells coordinate their contractions to maintain the continuous pumping activity required for life.
Unlike some other cell types, adult cardiomyocytes have a limited capacity to divide and replace damaged tissue.
When large numbers are destroyed during a heart attack, the body typically responds by activating repair mechanisms involving inflammation, connective tissue formation, and scar development.
Scar formation is not entirely harmful.
It helps stabilize an injured area and prevents certain structural complications.
The problem is that scar tissue cannot perform the electrical and mechanical functions of normal heart muscle.
A heart containing extensive scar tissue may gradually change shape, a process known as ventricular remodeling.
These structural changes can further impair pumping efficiency.
Regenerative medicine researchers have explored several strategies for addressing this problem.
Some approaches attempt to introduce therapeutic cells. Others investigate biological signals that might stimulate the body's own repair processes. Still others use engineered patches, scaffolds, or injectable materials to modify the environment surrounding damaged tissue.
Hydrogels are especially interesting because they may offer a way to introduce a biomaterial directly into the target region.
The material can potentially provide localized support without requiring the replacement of an entire section of the heart.
However, successful cardiac repair involves much more than generating new cells.
Any newly formed tissue would need an adequate blood supply, appropriate mechanical properties, and effective electrical integration with surrounding muscle.
Otherwise, even apparently promising tissue growth might fail to improve overall heart function.
A 2021 systematic review of experimental research involving tissue-engineered amniotic membranes described findings including reduced infarct size, improved cardiac function, and changes associated with tissue repair in animal models.
The review also highlighted the exploratory nature of the field and the need for further investigation.
This is why researchers cannot responsibly describe an experimental hydrogel as a proven cure.
Its ultimate value must be established through rigorous evidence, not simply through the attractiveness of the underlying concept.
From the Laboratory to a Potential Medical Treatment
Turning a hydrogel into a widely available therapy involves a long series of scientific and regulatory steps.
The first challenge is establishing that the material can be manufactured consistently.
Researchers need to know its composition, stability, biological activity, and behavior under conditions resembling those inside the human body.
They must also determine whether the material breaks down over time, whether its components remain where intended, and how surrounding tissue responds to its presence.
Safety is particularly important for an injectable cardiac treatment.
The heart operates through precisely coordinated electrical activity. Introducing a material into damaged tissue must not create unacceptable risks involving inflammation, rhythm disturbances, mechanical injury, or other complications.
Researchers must also investigate the most appropriate timing for treatment.
Would the gel be most useful shortly after a heart attack, when the injury is relatively recent?
Could it provide benefits months later, after substantial scar tissue has already formed?
Would different patients require different doses or delivery methods?
These questions cannot be answered through basic laboratory experiments alone.
They require carefully designed preclinical investigations and, eventually, controlled human studies.
In August 2026, Ferrer told LA NACION that the team expected to begin the regulatory pathway in 2027 and estimated roughly two years before the possible initiation of clinical trials.
These were development projections rather than confirmed trial schedules.
Even if early clinical studies begin successfully, the treatment would still need to demonstrate safety and meaningful effectiveness before it could become an accepted medical option.
Initial human trials often focus primarily on safety, tolerability, and feasibility.
Later studies may examine whether patients receiving a treatment experience better outcomes than those receiving existing care or an appropriate control intervention.
A larger clinical trial could assess changes in cardiac function, exercise capacity, symptoms, hospitalizations, or other outcomes important to patients.
The process is demanding because the consequences of introducing an ineffective or unsafe therapy into the heart could be serious.
Scientific caution is therefore not an obstacle to progress.
It is an essential part of making medical innovation trustworthy.
Scientists Have Already Tested Related Hydrogels in Humans
Although Ferrer's specific hydrogel has not been established as a human treatment, the wider field of injectable cardiac biomaterials has progressed beyond animal studies.